Rani Therapeutics (NASDAQ:RANI) Research Coverage Started at Maxim Group

Maxim Group began coverage on shares of Rani Therapeutics (NASDAQ:RANI) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $15.00 price target on the stock.

Several other research analysts have also weighed in on RANI. HC Wainwright raised their price objective on shares of Rani Therapeutics from $12.00 to $13.00 and gave the stock a buy rating in a report on Tuesday, May 7th. Canaccord Genuity Group decreased their price target on Rani Therapeutics from $21.00 to $9.00 and set a buy rating for the company in a research note on Wednesday, March 27th. Rodman & Renshaw began coverage on Rani Therapeutics in a research note on Thursday. They set a buy rating and a $10.00 price objective on the stock. Finally, BTIG Research increased their target price on Rani Therapeutics from $7.00 to $14.00 and gave the stock a buy rating in a report on Thursday, May 9th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Buy and an average target price of $12.29.

Rani Therapeutics Trading Down 1.2 %

NASDAQ:RANI opened at $4.03 on Friday. Rani Therapeutics has a one year low of $1.82 and a one year high of $8.75. The business’s 50-day simple moving average is $5.57 and its 200 day simple moving average is $4.10. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.09 and a current ratio of 3.09. The stock has a market cap of $203.19 million, a price-to-earnings ratio of -3.12 and a beta of 0.25.

Rani Therapeutics (NASDAQ:RANI) last released its earnings results on Monday, May 6th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). As a group, sell-side analysts predict that Rani Therapeutics will post -1.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rani Therapeutics

A hedge fund recently raised its stake in Rani Therapeutics stock. Vanguard Group Inc. lifted its stake in shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 685,303 shares of the company’s stock after purchasing an additional 16,956 shares during the quarter. Vanguard Group Inc. owned about 1.37% of Rani Therapeutics worth $2,131,000 as of its most recent filing with the Securities and Exchange Commission. 30.19% of the stock is owned by institutional investors and hedge funds.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.